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Zusammenfassung
Hintergrund: In der Vergangenheit wurde durch In-vitro-
und In-vivo-Tumormodelle belegt, dass Photofrin II als
spezifische, selektive radiosensibilisierende Substanz
wirken kann. Unsere Pilotstudie sollte die mögliche klini-
sche Anwendbarkeit von Photofrin II als strahlensensibi-
lisierende Substanz evaluieren. Patienten und Metho-
den: In die Studie wurden 12 Patienten eingeschlossen (7
inoperable Tumoren der Beckenregion, 3 maligne Glio-
me, 1 Rezidiv eines Oropharynxkarzinoms und 1 Rezidiv
eines Adenokarzinoms der Keilbeinhöhle). Die Dosis der
ionisierenden Bestrahlung betrug 30–50,4 Gy; für die Be-
ckenregion wurde eine Boostbestrahlung von 14 Gy hin-
zugefügt. 24 h vor Beginn der Strahlentherapie wurde 
1 mg/ml Photofrin II intravenös injiziert. MRT (Magnetre-
sonanztomographie)-Kontrollen und zum Teil PET (Posi-
tronen Emissions Tomographie) wurden in kurzen Zeit-
abständen durchgeführt. Der durchschnittliche Beobach-
tungszeitraum betrug 12,9 Monate. Ergebnisse: Schwer-
wiegende Nebenwirkungen traten nicht auf. Es wurden
nur geringfügige Nebenwirkungen wie leichte Diarrhö,
Übelkeit und Hautreaktionen beobachtet. Eine komplette
Remission trat bei 4/12 Patienten ein. Eine Reduktion des
lokalen Tumorvolumens von >45% wurde bei 4/12 Pa-
tienten erzielt. Ein stabiler Krankheitsverlauf lag bei 4/12
Patienten vor. Bei einem Patienten kam es nach 5 Mona-
ten zu einer lokalen Progression des Tumors. Schlussfol-
gerung: Die Ergebnisse der Nachkontrollen sind bezüg-
lich einer klinischen Anwendbarkeit von Photofrin II als
radiosensibilisierendem Agens ermutigend.
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Summary
Background: Photofrin II has been demonstrated to serve
as a specific and selective radiosensitizing agent in in
vitro and in vivo tumor models. We aimed to investigate
the feasibility of a clinical application of Photofrin II. Ma-
terial and Methods: 12 patients were included in the
study (7 unresectable solid tumors of the pelvic region, 
3 malignant gliomas, 1 recurrent oropharyngeal cancer, 
1 recurrent adenocarcinoma of the sphenoid sinus). The
dose of ionizing irradiation was 30–50.4 Gy; a boost irra-
diation of 14 Gy was added for the pelvic region. All pa-
tients were intravenously injected with 1 mg/kg Photofrin
II 24 h prior to the commencement of radiotherapy. Mag-
netic resonance imaging (MRI) controls and in some
cases positron emission tomography (PET) were per-
formed in short intervals. The mean follow-up was 12.9
months. Results: No major adverse events were noted.
Minor adverse events consisted of mild diarrhea, nausea
and skin reactions. A complete remission was observed
in 4/12 patients. A reduction in local tumor volume of
>45% was achieved in 4/12 patients. Stable disease was
observed in 4/12 patients. 1 patient showed local disease
progression after 5 months. Conclusion: The early fol-
low-up results are encouraging regarding the feasibility
of the application of Photofrin II as a radiosensitizing
agent.
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Introduction
The biological effects of radiation affect both neoplastic and
normal tissues. The nature and extent of such effects, however,
depend on selected biological parameters (e.g. oxygen supply,
cell cycle) and can be modified by chemical agents, such as ra-
diosensitizers, radioprotectors and chemotherapeutic agents
[1]. This modification is important in order to achieve the
maximum effect on tumor tissue, while at the same time mini-
mizing the effect on normal tissue.
The selectivity of ionizing radiation, which is often relatively
low for tumor as compared to normal tissue, can be improved
by using computer-controlled irradiation protocols with dif-
ferent types of radiation. Moreover, the effect of radiation on
tumor tissues can be optimized, as mentioned, by the addition
of radiosensitizing agents, in order to achieve greater damage
to the neoplastic tissue than would be expected from the addi-
tive effect of each modality. However, local failure is com-
monly observed, even for this combined therapeutic strategy,
with local failure rates being as high as 60–80% at the time of
death [2].
When using radiosensitizing agents, 2 main parameters must
always be considered – the probability of local tumor control
(corresponding to the therapeutic ratio) and the probability
of complications. Most of the presently known and routinely
used radiosensitizing agents have a poor selectivity and are
not tumor-specific. The use of these compounds may also re-
sult in severe side effects due to their inherent toxicity [2].
During the 1980s, photodynamic therapy (PDT) began to
emerge as a promising alternative for the treatment of early
and localized tumors in which adequate local surgery is diffi-
cult, such as multifocal bladder cancer [3]. The technique in-
volves the topical or systemic administration of a photosensi-
tizing agent which is preferentially accumulated or retained
by the tumor tissue, followed by illumination of the neoplastic
area with light wavelengths specifically absorbed by the pho-
tosensitizer [4–5]. In this context, porphyrins and their ana-
logues are most frequently used as photosensitizers. Their
tetrapyrrolic macrocycle exhibits absorption bands in the red
region of the visible spectrum (600–800 nm), which is en-
dowed with a particularly high penetration power into human
tissue [6]. At present, the main photosensitizer in clinical use
for PDT treatments is Photofrin II® (Axan, Mont-Saint-Hi-
laire, Canada), a complex mixture of porphyrins produced
through acid treatment of hematoporphyrin derivative (HpD)
[7]. Photofrin II has recently been approved as a photosensi-
tizing agent in the clinical treatment of selected solid tumors
[3–5].
The preferential affinity displayed by Photofrin for tumors as
compared to most normal tissues was the driving force in
prompting studies aimed at investigating the possible use of
porhyrins as tumor-sensitizers during radiotherapy. Specifical-
ly, the use of Photofrin as a radiosensitizer would be advanta-
geous, since a single chemical agent could be injected and in-
crease the sensitivity of tumor tissue to both ionizing and non-
ionizing radiation.
Several recently published studies on tissue cultures and on
murine tumor models have demonstrated the in vitro and in
vivo efficacy of Photofrin II as both a specific and a selective
radiosensitizing agent [8–12]. These animal studies have as-
sessed the efficacy of the radiosensitizing action in terms of
tumor doubling time (∆t), i.e. the time interval for the tumor
volume to double as compared to the volume at the time of ir-
radiation. The ∆t value was found to be 6.2 days for non-irra-
diated cancer (control cases) and increased to 10.9 days in the
group of mice exposed to a combination of ionizing radiation
and Photofrin II. The mechanism of action of Photofrin II as a
radiosensitizer is not clear [8–12]. The radiosensitizing process
of Photofrin II may involve the oligomeric porphyrin con-
stituents which are enriched in Photofrin [8–12]. More specifi-
cally, it may involve clusters of stacked tetrapyrrolic macrocy-
cles along which any unpaired electrons generated via an in-
teraction of Photofrin with OH and O2 radicals may readily
delocalize along the tetrapyrrolic macrocycles, thereby stabi-
lizing the porphyrin radical and allowing its diffusion over rel-
atively large distances from the initial point of generation. In
addition, Photofrin II may minimize the possible onset of re-
pair processes which often limit the radio-induced cellular
damage. Other observations already published in the 1950s
and 1960s by Schwartz and Cohen [13–15] and later by other
groups [16] have demonstrated that HpD acts as a radiosensi-
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Table 1. Patient population treated with Photofrin II as a radiosensitizer
Patients, Sex Diagnosis
n
Male Female
3 2 1 bladder carcinoma
1 1 – recurrent bladder carcinoma
1 – 1 cervical cancer, FIGO IV
2 – 2 pelvic sarcoma
3 2 1 astrocytoma, WHO grade III
1 1 – recurrent oropharyngeal carcinoma 
1 1 – recurrent adenocarcinoma of the 
sphenoid sinus 
Table 2. Side effects
Side effects Patients, n

WHO I WHO II WHO III WHO IV
Skin 3 – – –
Rectal bleeding – – – –
Diarrhea 2 2 – –
Cystitis 4 – – –
Nausea 3 1 – –
Vomiting 2 1 – –
tizing agent in the treatment of tumors. HpD is a highly het-
erogeneous chemical derivative of Hp of which Photofrin II
represents a partially purified form [7].
The primary aim of this study was to evaluate the feasibility of
a clinical application of Photofrin II as a radiosensitizer in var-
ious solid tumors. In addition, a preliminary evaluation of the
potential efficacy of the substance was to be performed.
Patients and Methods
A feasibility study was performed to evaluate the feasibility of the appli-
cation of Photofrin II as a radiosensitizer, to assess the toxicity of the com-
bination of Photofrin II and ionizing radiation, and to then find the opti-
mal dose of Photofrin II as a radiosensitizing agent. In addition, prelimi-
nary data on the potential efficacy of the substance were to be gathered.
In this feasibility study, no dose escalation was performed.
After approval from the local Institutional Review Board, a combined
treatment of irradiation and Photofrin II as a possible selective radiosen-
sitizer was offered. All patients gave informed consent to this treatment,
conforming to the guidelines of Good Clinical Practice. Patients were ad-
vised to avoid direct contact with light and to especially protect their eyes
in the first days after therapy due to the known photosensitivity of por-
phyrins [3–5]. All patients received a specially equipped room which was
completely shielded from sunlight and was equipped with lighting not
stronger than 40 W.
A total of 12 patients were included in the study (5 female, 7 male, mean
age 53.6 years). 7 patients had unresectable solid tumors in the pelvic 
region (4 cases of bladder cancer, 2 pelvic sarcomas and 1 cervical can-
cer), 3 had a malignant glioma (WHO grade III), 1 male patient had re-
current oropharyngeal cancer and another male patient a recurrent ade-
nocarcinoma of the sphenoide sinus (table 1). In all 7 patients with pelvic
tumors, concomitant administration of chemotherapy was contraindicat-
ed. 1 of the 3 patients with malignant glioma was suffering from a tumor
recurrence.
The applied dose of ionizing irradiation ranged between 44.4 and 50.4 Gy;
a boost irradiation with 14 Gy was added for the pelvic region. In the ma-
lignant glioma cases, the irradiation dose was 30 Gy in the patient with
tumor recurrence, as this patient had undergone irradiation with 60 Gy in
the past, and 40 Gy + 20 Gy boost in the other patients. The patient with
recurrent oropharyngeal carcinoma was treated with brachytherapy at a
dose of 30 Gy, while the patient with recurrent carcinoma of the sphenoid
sinus was treated with external beam irradiation at a dose of 45 Gy plus a
14 Gy boost. All patients were intravenously injected with a single dose of
1 mg/kg Photofrin II 24 h prior to the commencement of radiation thera-
py. We chose to apply our boost irradiation at the time of peak Photofrin
II concentrations in order to achieve the maximum effect on the tumor
tissue. Pharmakokinetic studies of Photofrin II and past in vivo experi-
ments [9, 11] have demonstrated the main therapeutic window of
Photofrin II to be in the first week of application.
The relative serum levels of Photofrin II were evaluated prior to the initi-
ation of therapy. Subsequently, daily Photofrin II levels were assessed.
The methodology applied was a reversed-phase ion-pairing high perfor-
mance liquid chromatography (HPLC) with fluorescence detection after
solid-phase extraction using the pure drug substance of Photofrin for cali-
bration [17]. Magnetic resonance imaging (MRI) with a standardized pro-
tocol was performed prior to the initiation of therapy, immediately after
the conclusion of therapy, and every 2–3 months thereafter. In 5 patients,
positron emission tomography (PET) was performed in addition after the
conclusion of therapy.
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Patients, Diagnosis Follow-up, Results
n months
1 cervical cancer, FIGO IV 27 complete remission; disease-free
2 pelvic sarcoma 28 complete remission; disease-free
3 recurrent astrocytoma, WHO III 5 tumor progression after 5 months, patient died 
4 bladder carcinoma 12 45% reduction in tumor volume; then R0 
resection; patient died of distant metastases, 
no local recurrence 
5 bladder carcinoma 4 no change in tumor volume; patient died of 
distant metastases
6 bladder carcinoma 4 in PET only marginal tumor vitality; patient died
of myocardial infarction
7 local recurrence of bladder carcinoma 11 35–40% reduction in tumor volume; patient 
declined surgery; lost to follow-up after 
11 months; during this time no tumor progression
8 astrocytoma, WHO III 15 no change in tumor volume; subsequently treated
with chemotherapy
9 astrocytoma, WHO III 14 no change in tumor volume; in FET-PET no 
signs of tumor vitality; disease-free
10 pelvic sarcoma 16 45% tumor reduction; subsequently treated with 
chemotherapy and hyperthermia
11 recurrent adenocarcinoma of the sphenoid 4 40% reduction of volume; in FET-PET no signs 
sinus of tumor vitality; disease-free
12 recurrent oropharyngeal carcinoma 3 no change in tumor volume
FET-PET = 18F-fluoroethyl-L-tyrosine positron emission tomography.
Table 3. Early
clinical results after
application of
Photofrin II as a
radiosensitizer
Results
No major adverse events of the therapeutic regimen were
noted in our patient population. Observed minor adverse
events consisted of mild diarrhea, nausea and skin reactions
(table 2). These minor adverse events of the therapeutic regi-
men did not significantly differ from the side effects routinely
encountered with sole radiation therapy. Skin reactions, such
as edema, erythema or other lesions, related to the photosen-
sitizer (Photofrin II) were not seen or observed.
The relative serum level of Photofrin II peaked in the first 5–6
days after intravenous injection, followed by a subsequent
steep decrease [17]. This timeframe correlates well with the
therapeutic window. 
Table 3 summarizes the follow-up data of our patient popula-
tion with regard to tumor size as demonstrated by MRI and/or
PET. The mean follow-up time was 12.9 months (range 4–32
Onkologie 2006;29:514–519Feasibility of Photofrin II as Radiosensitizer 517
 
 
A 
B 
Fig. 1. A Axial T1- and B coronal T2-weighted MR images prior to
therapy (after administration of paramagnetic contrast medium) demon-
strate a large cervical carcinoma in a 60-year-old patient involving almost
two thirds of the uterus. The neoplastic tissue is relatively hyperintense as
compared to the adjacent myometrium. Rectum and vagina were filled
with a hydrophilic gel to optimize contrast.
 
 
A 
B 
Fig. 2. A Axial T1- and B coronal T2-weighted MR images 12 months
after the conclusion of therapy demonstrate an almost complete remission
of the tumor. Only a very slight, small hyperintensity is present in the cer-
vical region.
months). In the majority of patients, a significant reduction in
tumor volume was observed. Complete clinical remission was
found in 4/12 patients (1 pelvic sarcoma, 1 cervical cancer,
1 astrocytoma and 1 sphenoid adeno-carcinoma) (fig. 1, 2). A
reduction in local tumor volume of > 45% was achieved in
4/12 patients; 1 of these patients was lost to follow-up after 12
months. Stable disease was observed in 4/12 patients. 1 patient
with an astrocytoma grade III had a local disease progression
after 5 months. In addition, PET showed no tumor vitality in 
4 of the 5 patients examined.
Discussion
The present work demonstrates the feasibility of a clinical ap-
plication of Photofrin II as a radiosensitizing agent. The thera-
peutic dose range of Photofrin II as a photodynamic agent
ranges between 1.0 and 2.5 mg/kg [18]. Since no literature is
currently available on the dosage of Photofrin II as a ra-
diosensitizing agent, we decided to treat with the lowest dose
known to be therapeutic for PDT in order to avoid unknown
complications, even though it had been demonstrated in the
past that the presence of other porphyrins during irradiation
does not enhance the local side effects of radiotherapy [19]. In
this early phase of clinical testing, a dose escalation has not yet
been performed. It will, however, be the aim of future studies
to investigate a dose escalation of Photofrin II as a radiosensi-
tizing agent.
As mentioned above, one of the limiting factors of the clinical
application of Photofrin II may be its photosensitivity. The
main strategy to avoid this complication consists in shielding
the patients from sunlight and providing a specially equipped
room with lighting at or below 40–60 W. The period during
which shielding from light is required, differs from patient to
patient and largely depends on liver function and general me-
tabolism. Dougherty et al. [18] demonstrated that patients
having received a relatively low dose (1 mg/kg) displayed a
longer period of skin sensitivity than patients having received
a dose of 2.5 mg/kg. Moreover, when Shikowitz et al. [20]
treated patients with PDT at the high dose of 4.5 mg/kg
Photofrin II, the observed skin sensitivity was not increased in
comparison to lower doses. We generally protected our pa-
tients from sunlight and light above 40 W for about 30 days
depending on the Photofrin II serum levels in the HLPC. In
our study population, we observed only minor skin reactions.
No major adverse events, specifically no major skin reactions,
were found.
The therapeutic concentration of Photofrin in the tumor tissue
was demonstrated to be reached between 24 and 72 h after in-
jection [3–6, 21, 22]. This correlates well with the serum
Photofrin II levels in our patient population as measured by a
reversed-phase ion-pairing HPLC with fluorescence detection
after solid-phase extraction using the pure drug substance of
Photofrin for calibration. We chose to apply our boost irradia-
tion at the time of peak Photofrin II concentrations in order to
achieve the maximum effect on the tumor tissue.
In the past, the radiosensitizing effect of Photofrin II has been
demonstrated in vitro and in animal models. The radiosensitiz-
ing effect was shown even in tumor models known to be highly
radioresistant, such as glioblastoma and bladder carcinoma
[12]. Photofrin alone caused no appreciable tumor response
even at concentrations that yielded a marked radiosensitizing
effect in the experimental setting. The combined action of
Photofrin and ionizing radiation seems to be a saturable
process [8, 9]. Animal experiments have demonstrated the ra-
diosensitizing activity of Photofrin II under optimal conditions
to approach a factor of 3 [8, 9]. Other commercially available
porphyrins were shown not to act as radiosensitizers but only
as photosensitizers during PDT [9, 10]. An exception is repre-
sented by Gd-Tex that has been demonstrated to act as a radia-
tion sensitizer both in vivo and in vitro [23, 24] However, some
controversy remains regarding its efficacy [25]. Synthetic met-
allo-porphyrins have also shown a radiosensitizing effect [26].
The mechanism by which Photofrin II acts as a radiosensitizer
is not yet completely understood. Regardless of its mechanism
of action, however, past in vitro and animal studies and our
current early clinical experiences appear promising.
Our study has several limitations that need to be taken into
account when interpreting the data. First, our patient popula-
tion is relatively small and heterogeneous in regard to the type
of tumor. Second, the follow-up times are still limited with a
mean follow-up time of 12.9 months. Moreover, the study de-
sign of this phase I study is inherently without randomization
or a control group, thus limiting interpretations regarding the
efficacy of the therapeutic regimen. However, in this current
study, we primarily focused on the feasibility of the clinical use
of Photofrin II as a radiosensitizer and its potential toxicity.
As the results appear encouraging, further studies, including
dose escalation studies, and eventually larger, randomized,
multicenter studies are warranted
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